^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    B4GALNT1 expression

    i
    Other names: B4GALNT1, Beta-1,4-N-Acetyl-Galactosaminyltransferase 1, UDP-N-Acetyl-Alpha-D-Galactosamine:(N-Acetylneuraminyl)-Galactosylglucosylceramide N-Acetylgalactosaminyltransferase (GalNAc-T), UDP-Gal:BetaGlcNAc Beta-1,4-N-Acetylgalactosaminyltransferase Transferase 1, Beta-1,4 N-Acetylgalactosaminyltransferase 1, GD2 Synthase, GM2 Synthase, GM2/GD2 Synthase, GalNAc-T, GALGT, (N-Acetylneuraminyl)-Galactosylglucosylceramide, Beta-1,4-N-Acetyl-Galactosaminyl Transferase 1, Spastic Paraplegia 26, Beta1,4G
    Entrez ID:
    2583
    3ms
    Downregulation of B4GALNT1 inhibits proliferation and metastasis of osteosarcoma cells. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban)
    B4GALNT1 is upregulated in osteosarcoma tissues and cell lines, and its knockdown suppresses the malignant phenotype of osteosarcoma cells. B4GALNT1 may function as an oncogene in the proliferation and metastasis of osteosarcoma cells.
    Journal
    |
    VIM (Vimentin) • B4GALNT1 (Beta-1,4-N-Acetyl-Galactosaminyltransferase 1) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9)
    |
    B4GALNT1 expression • VIM expression
    1year
    B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin α2β1-mediated FAK and AKT activation. (PubMed, JHEP Rep)
    Here, we reveal that B4GALNT1 has a crucial role in HCC stemness and progression by activating the integrin α2β1/FAK/PI3K/AKT axis, providing a potential target for HCC therapy. In addition, we find Ophiopogonin D as a potential therapeutic drug for patients with HCC.
    Journal
    |
    B4GALNT1 (Beta-1,4-N-Acetyl-Galactosaminyltransferase 1) • ITGB1 (Integrin Subunit Beta 1) • THBS4 (Thrombospondin 4)
    |
    B4GALNT1 expression
    over1year
    B4GALNT1 promotes carcinogenesis by regulating epithelial-mesenchymal transition in hepatocellular carcinoma based on pan-cancer analysis. (PubMed, J Gene Med)
    B4GALNT1 may promote HCC development through regulating the EMT pathway, which suggests that B4GALNT1 may serve as a promising predictive biomarker and a potential therapeutic target for HCC.
    Journal • IO biomarker • Pan tumor
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • B4GALNT1 (Beta-1,4-N-Acetyl-Galactosaminyltransferase 1)
    |
    BCL2 expression • B4GALNT1 expression
    over2years
    ASSESSING PREDICTIVE VALUE OF RNA-SEQ OF B4GALNT1 AND ST8SIA1 AS BIOMARKERS OF GD2 EXPRESSION IN PEDIATRIC SARCOMAS (CTOS 2022)
    Objective: GD2 is a tumor-associated ganglioside that is highly expressed in neuroblastoma and is targeted by two FDA-approved agents, dinutuximab and naxitamab. RNA expression of B4GALNT1 seemed to correlate and cluster better with known levels of GD2 expression than ST8SIA1 in neuroblastoma patients who historically have very high levels of GD2 expression via IHC. In sarcomas, MPNSTs had expression levels higher than that of even osteosarcoma which has been the center of clinical trials in sarcomas for GD2-targeted therapy. Given the response of bone disease with dinutuximab and naxitinib in pediatric patients with neuroblastoma, it suggests potential utility of treatment in sarcomas outside of neuroblastoma.
    Clinical
    |
    B4GALNT1 (Beta-1,4-N-Acetyl-Galactosaminyltransferase 1) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
    |
    B4GALNT1 expression
    |
    Danyelza (naxitamab-gqgk) • Unituxin (dinutuximab)